Loading organizations...
SamaCare automates the prior authorization process, helping medical practices save time and resources while focusing on patient care.
SamaCare has raised $29.0M across 2 funding rounds.
SamaCare has raised $29.0M in total across 2 funding rounds.
SamaCare has raised $29.0M in total across 2 funding rounds.
SamaCare's investors include Questa Capital, South Park Commons, Cheryl Cheng, NextView Ventures, Susa Ventures.
SamaCare has raised $29.0M across 2 funding rounds. Most recently, it raised $17.0M Series B in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2024 | $17M Series B | Questa Capital | South Park Commons, Cheryl Cheng | Announced |
| Jun 2, 2022 | $12M Series A | Cheryl Cheng | NextView Ventures, South Park Commons, Susa Ventures | Announced |
SamaCare is a healthcare technology company that builds a cloud-based SaaS platform automating prior authorizations for specialty medications, serving medical practices in retina, oncology, neurology, and rheumatology—fields representing over $20 billion in annual drug spend.[1][2][3] It solves the administrative bottleneck of manual prior authorization submissions, tracking, and management across payers, reducing time spent by nearly 50% and enabling providers to focus more on patients; the platform is free for practices, integrates with any EMR, and offers AI-driven features like auto-fills and touchless processing.[1][2][5] Pharma partners gain data analytics to cut abandonment rates by 24%, approval times by 84%, and denials by 42%, while providers benefit from actionable insights and paperless workflows; with over 15,000 providers and 2,300 prescribers using it, SamaCare has raised $12M Series A and $17M Series B, signaling strong growth momentum.[2][3][5]
Founded in 2018 in San Francisco by Syam Palakurthy (CEO), SamaCare emerged to tackle the inefficiencies in specialty drug prior authorizations, a process often delaying patient access to therapies.[1][2] Palakurthy's vision focused on workflow automation for high-stakes medical practices, quickly gaining traction with over 2,300 prescribers and partnerships with major pharmaceutical companies.[2] Pivotal moments include the 2022 $12M Series A led by Vive Collective and Questa Capital, expanding reach in retina and oncology, followed by a $17M Series B to scale across neurology and rheumatology, alongside the launch of AI-powered SamaCare Plus for touchless authorizations.[2][3][4][6]
SamaCare rides the wave of digital health automation amid rising specialty drug costs and regulatory scrutiny on prior authorizations, a process plaguing U.S. healthcare with delays that impact outcomes.[1][2] Timing aligns with AI adoption in revenue cycle management—post-2023 failures like Olive highlight resilient players like SamaCare—and payer-provider tensions favoring interoperable platforms.[1] Market forces include exploding demand for retina/oncology/neurology therapies, pharma's push for real-world access data, and CMS mandates for faster auths; by influencing point-of-care decisions, SamaCare shapes ecosystem efficiency, competing with Arrive Health and eBlu while enabling better therapy adherence.[1][2]
SamaCare is poised to dominate specialty prior auth with AI expansions like SamaCare Plus, targeting deeper pharma integrations and broader specialties amid $20B+ markets.[3][4] Trends like payer consolidation, value-based care, and generative AI will accelerate its growth, potentially capturing more of the fragmented RCM space. Its influence may evolve into a full therapy access hub, further reducing delays and powering outcomes-driven healthcare—streamlining the path from prescription to patient, just as its platform does for providers today.[2][5]
